Profil bibliographique

Tomáš Jelı́nek

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

725Publications signalées

14054Citations signalées

2Affiliations récentes

Institutions déclarées

University of Ostrava University Hospital Ostrava

Domaines associés

Multiple Myeloma Research and TreatmentsBoron Compounds in ChemistryMalaria Research and ControlMosquito-borne diseases and controlProtein Degradation and Inhibitors

Publications récentes

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Maximilian Merz, Tomáš Jelı́nek, Thomas Pabst, Raphael Teipel et autres

0 citations

Accès ouvert 2026 otherOpenAlex

Data from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Maximilian Merz, Tomáš Jelı́nek, Thomas Pabst, Raphael Teipel et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Maximilian Merz, Tomáš Jelı́nek, Thomas Pabst, Raphael Teipel et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S2 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Maximilian Merz, Tomáš Jelı́nek, Thomas Pabst, Raphael Teipel et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Maximilian Merz, Tomáš Jelı́nek, Thomas Pabst, Raphael Teipel et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S4 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Maximilian Merz, Tomáš Jelı́nek, Thomas Pabst, Raphael Teipel et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Table S2 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Maximilian Merz, Tomáš Jelı́nek, Thomas Pabst, Raphael Teipel et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Methods 1 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Maximilian Merz, Tomáš Jelı́nek, Thomas Pabst, Raphael Teipel et autres

0 citations

Accès ouvert 2026 supplementary-materialsOpenAlex

Supplementary Figure S3 from Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Maximilian Merz, Tomáš Jelı́nek, Thomas Pabst, Raphael Teipel et autres

0 citations

Accès ouvert 2026 articleOpenAlex

Anti‐BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma

Ondrej Venglár, Eva Radova, Maxima Warmuzová, Daniel Bilek et autres

0 citationsHemaSphere

2026 articleOpenAlex

Talquetamab–Daratumumab in Relapsed or Refractory Myeloma

Roberto Mina, Meral Beksac, Paula Rodríguez‐Otero, Wenming Chen et autres

9 citationsNew England Journal of Medicine

Accès ouvert 2026 articleOpenAlex

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma

Maximilian Merz, Tomáš Jelı́nek, Thomas Pabst, Raphael Teipel et autres

0 citationsBlood Cancer Discovery

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.